Compugen Ltd. (CGEN) differentiates itself from traditional biotech peers through its proprietary computational biology discovery engine, which uses predictive artificial intelligence rather than standard wet-lab trial-and-error methods to target immune system pathways. While many clinical-stage peers experience high capital burn rates with prolonged developmental timelines, Compugen's unique platform model has successfully attracted high-profile licensing agreements with global pharmaceutical giants.